ZYBERNO
Stock Report
Updated Sep 1, 2026

BioXcel Therapeutics, Inc. (BTAI)

Healthcare • NASDAQ

$0.16

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
BioXcel Therapeutics, Inc. (BTAI) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-6,054.7%)
Return on Capital (Capital Efficiency):CRITICAL (-41.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BioXcel Therapeutics, Inc. (BTAI) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.16
Market Cap:$4.93M

Valuation Multiples (2)

P/S Ratio:6.65x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$200.99M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (4)

ROA:-185.8%
Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-0.4%

Margin Analysis (3)

Operating Margin Ttm:-6,054.7%
Net Margin Ttm:-9,549.9%
Ebitda Margin:-6,024.4%

TTM Performance (3)

Gross Margin Ttm:53.1%
Operating Margin Ttm:-6,054.7%
Net Margin Ttm:-9,549.9%

Yield Metrics (2)

Earnings Yield:-$577.78
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:81.7%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-15.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.21x
Quick Ratio:0.21x
Cash Ratio:0.09x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.93x
Times Interest Earned:-2.93

Capital Structure (4)

Working Capital:-108,449,000.00
Cash And Cash Equivalents:12,841,000.00
Long Term Debt:$104.45M
Net Debt:$196.06M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $742.00K
Linear Growth: -15.3%
📊 Click to view full BTAI Revenue analysis & methodology →
Cost Of Revenue Ttm:$348.00K

Profitability Breakdown (2)

Gross profit TTM: $394.00K
Linear Growth: -24.9%
📊 Click to view full BTAI Gross Profit analysis & methodology →
-$44.93M

Bottom Line Performance (3)

-$70.86M
Income Before Tax:$0.00
Ebitda Ttm:-44,701,000.00

Operating Expenses (5)

Operating Expenses:45,668,000.00
R And D Expense:21,560,000.00
Sga Expense:23,566,000.00
Income Tax Expense:$0.00
Interest Expense:17,224,000.00

Expense Ratios (3)

R And D To Revenue Percentage:11,846.2%
Sga To Revenue Percentage:12,948.4%
Ebitda Margin:-6,024.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$28.80M
Current Assets:$28.70M
Ppe Net:1,977,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:144,259,000.00
Current Liabilities:137,149,000.00
Long Term Debt:$104.45M
Short Term Debt:$104.45M

Equity & Capital (3)

Equity:-$115.46M
Retained Earnings:-$747.50M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:82,000.00
Inventory:483,000.00
Accounts Payable:18,783,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:358,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$57.38M-$57.62M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$232.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,498,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$8.11M

Non-Cash Items (1)

Depreciation Amortization Ttm:225,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-6.76
-$6.76
Earnings Per Share Ttm:-$2.34

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.02
Operating Cash Flow Per Share:-$1.90

Book Value & Capital (2)

Book Value Per Share:-$3.81
Cash Per Share:0.42

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:9.05x
Days Sales Outstanding Ttm:40.34

Inventory Management (2)

Inventory Turnover Ttm:0.72x
Days Inventory Outstanding Ttm:506.59

Payables & Cash Cycle (2)

Days Payable Outstanding:19,700.56
Cash Conversion Cycle:-19,153.63
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-0.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-15.3%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-24.9%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:BTAI
Company Name:BioXcel Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:30.30M
Shares Outstanding Basic:30.30M
Shares Outstanding Diluted:30.30M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 07:07:07 UTC
Data Timestamp:2026-08-20T18:46:47.806204
Scroll to Top